Deafness-lymphedema-leukemia syndrome

Deafness-lymphedema-leukemia syndrome, also known as Emberger syndrome, is an extremely rare genetic disorder characterized by the triad of sensorineural hearing loss, primary lymphedema, and a predisposition to myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The condition is caused by heterozygous loss-of-function mutations in the GATA2 gene, which encodes a transcription factor critical for hematopoietic stem cell function, lymphatic vascular development, and inner ear development. The hearing loss is typically bilateral and sensorineural, often presenting in childhood. Lymphedema, which involves swelling due to impaired lymphatic drainage, primarily affects the lower limbs and may be present from birth or develop later. The hematologic manifestations, classified under myelodysplastic syndromes (ICD-10: D46.7), represent the most life-threatening aspect of the disease, as patients have a significantly elevated risk of developing MDS that can progress to AML, often in adolescence or young adulthood. The syndrome affects multiple body systems including the hematopoietic (blood-forming) system, the lymphatic system, and the auditory system. Some patients may also present with warts or other signs of immunodeficiency related to GATA2 haploinsufficiency. Additional features can include hydrops fetalis and genital lymphedema. Management is multidisciplinary and includes audiological support for hearing loss, compression therapy and physiotherapy for lymphedema, and close hematologic monitoring. For patients who develop MDS or AML, allogeneic hematopoietic stem cell transplantation (bone marrow transplant) is currently the only curative treatment for the hematologic component. Genetic counseling is recommended for affected families. Early diagnosis through genetic testing of GATA2 is important for surveillance and timely intervention.

Common questions about Deafness-lymphedema-leukemia syndrome